ReviewClinical optometry2022
A Review of Ocular Complications Associated with Medications Used for Anxiety, Depression, and Stress.
Review in Clinical optometry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Beyond the vision: central serous chorioretinopathy, anxiety and depression-a systematic review.Frontiers in medicine · 2025Pooled it
- Monitoring and addressing anticholinergic-induced ocular adverse effects associated with psychotropic medication.The mental health clinician · 2026Article
- Conjunctival goblet and epithelial cell changes in antidepressant-associated dry eye disease: a case-control study.BMC ophthalmology · 2026Article
- Article
- The Real-World Safety Profile of Temazepam: A 20-Year Pharmacovigilance Analysis Based on the Large-Scale FAERS Database.CNS neuroscience & therapeutics · 2026Article
- Factors Affecting Postoperative Satisfaction After Presbyopia-Correcting Intraocular Lens.Journal of clinical medicine · 2026Review
- Analysis of ocular adverse events associated with SNRIs.Frontiers in pharmacology · 2026Article
- Integrated management of dry eye-depression comorbidity: mechanistic insights and temporal therapeutic strategies.Frontiers in medicine · 2026Article
- Management of Dry Eye Disease with Artificial Tears Containing Hyaluronic Acid and Trehalose: A Narrative Review.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Persistent and Dose-Dependent Neural and Metabolic Gene Expression Changes Induced by Transient Citalopram Exposure in Zebrafish Embryos.International journal of molecular sciences · 2025Article
- Dry Eye Disease and Psychiatric Disorders: Neuroimmune Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2025Review
- Risk of retinal disease and visual impairment in individuals with psychiatric disorders.Eye (London, England) · 2025Article
- Associations between physiological indicators of cochlear deafferentation and listening effort in military Veterans with normal audiograms.Hearing research · 2025Article
- Decreasing Preoperative Anxiety in Patients with Newly Available Multimodal Approaches-A Narrative Review.Journal of clinical medicine · 2025Review
- Intraoperative Iris Behavior during Phacoemulsification Maneuvers in Rabbits Treated with Selective α1-Blocker, 5α-Reductase Inhibitor, or Anxiolytic Medication.Journal of personalized medicine · 2024Article
- Solar retinopathy related to antidepressant use in a patient with major depressive disorder: a case report.Journal of Yeungnam medical science · 2024Article
- Glaucoma Detection through a Novel Hyperspectral Imaging Band Selection and Vision Transformer Integration.Diagnostics (Basel, Switzerland) · 2024Article
- Review
- Comparing the Efficacy of Escitalopram with and without Crocin in Restoring I/O Functions and LTP within the Hippocampal CA1 Region of Stressed Rats.Advanced biomedical research · 2024Article
- Benefits of Urban Forest Healing Program on Depression and Anxiety Symptoms in Depressive Patients.Healthcare (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review of commonly prescribed psychotropic drugs aims to update the clinician on possible ophthalmic side effects that may include dry eye, diplopia, mydriasis, and cataracts. This review summarizes our current knowledge of known ocular side effects of psychotropic drugs based on reviews, case reports, case-control studies, a case series, and cross-sectional observational studies reported in the recent literature. The review covers disorders related to depression, anxiety, and stress which are commonly encountered within society and can have debilitating impacts on an individual's quality of life that may require chronic therapeutic management. The main medications used in the treatment and management of these conditions typically target receptors, metabolic enzymes, or transport pumps that alter the pre- and/or post-synaptic levels of neurotransmitters such as serotonin, norepinephrine, dopamine, gamma-aminobutyric acid, and opioids to improve mood and/or relieve pain and anxiety. Novel non-therapeutic options are undergoing clinical trials, and some patients may seek alternative therapies or have associated substance abuse issues to alleviate their symptoms. This review summarizes some of the clinical signs of depression and the main therapeutic options and their reported ocular side effects which may be pertinent today given the rise in use of psychotropic medications used to manage depression, anxiety, and stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.